HomeSearchGlobal LocationsContact UsGenzyme Websites
About GenzymeOur ResearchOur ProductsOur Commitment
Genzyme

Corporate Info
Investors
News
Press Contacts
Press Kits
News Coverage
News Subscription
Partnering
Genzyme Events
Careers
Global Locations

News

Press Releases

Genzyme
August 25, 2008Genzyme Corporation and Medicines for Malaria Venture Announce New Collaboration with Advinus Therapeutics to Accelerate Discovery of Novel Therapies for Malaria
August 6, 2008Genzyme and Isis Begin Second Phase 3 Trial of Mipomersen
July 23, 2008Genzyme Reports Strong Second-Quarter Growth
July 17, 2008Genzyme Corporation and PTC Therapeutics Announce Collaboration on Small Molecule for Genetic Diseases
June 24, 2008Genzyme and Isis complete licensing of mipomersen
June 17, 2008Genzyme Files Applications for Approval of Mozobil in the United States and Europe
June 2, 2008Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
May 7, 2008Preliminary Results from Phase 2 Genzyme Study
April 25, 2008FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen
April 23, 2008Genzyme Reports Strong First-Quarter Growth
April 22, 2008Genzyme to Build New R&D Center in Beijing
April 21, 2008Genzyme Provides Update on Myozyme® Manufacturing
April 14, 2008Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy
March 19, 2008Genzyme Withdraws Bioenvision’s European Filing of Evoltra® in Elderly AML Patients
March 10, 2008Genzyme Announces Presentation of New Positive Data on Carticel®
March 6, 2008Genzyme Launches Renvela® in the U.S. for Dialysis Patients
February 13, 2008Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year
February 1, 2008University of Massachusetts and Genzyme Launch Genzyme/UMass Scholars Program
February 1, 2008Genzyme and Isis Announce Hart-Scott-Rodino Approval Of Collaboration
January 15, 2008Genzyme Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Lung Cancer Diagnostic
January 8, 2008Genzyme Reports 21 Percent Increase in Fourth-Quarter Revenue
January 7, 2008Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
December 19, 2007Genzyme Receives European CE Mark for Single-Treatment Synvisc-One™
December 17, 2007Genzyme Announces FDA Approval of Thyrogen® For Use In Thyroid Cancer Ablation
December 13, 2007Genzyme Study of Myozyme® for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
December 5, 2007Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML
December 4, 2007National Cancer Institute Study to Determine the Optimal Time for CLL Patients to Begin Treatment
November 13, 2007Genzyme Receives FDA Response Letter on Synvisc-One™
October 29, 2007Epicel™ Wins Marketing Approval for Severe Burn Victims
October 25, 2007Genzyme and Sunway to Collaborate on Gene Therapy Program in China
October 24, 2007Genzyme Reports Strong Earnings Growth in Third Quarter
October 23, 2007Genzyme Launches Cholestagel® in Europe
October 22, 2007Bioenvision Shareholders Approve Acquisition by Genzyme Corporation
October 22, 2007FDA Approves Genzyme's Renvela for Dialysis Patients
October 16, 2007Genzyme Statement Regarding Results of FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
October 15, 2007Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis
October 12, 2007Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
October 12, 2007Genzyme Recognized by Scientists as a Top Employer
October 10, 2007Delaware Court Approves Bioenvision, Genzyme Joint Petition
October 10, 2007Bioenvision and Genzyme File Petition in Delaware Court
October 4, 2007Genzyme Receives Approval to Market Elaprase® in Japan
September 27, 2007Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
September 26, 2007Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
September 20, 2007FDA Approves Expanded Labeling for Campath® to Include First-line Treatment for Leading Form of Adult Leukemia
September 18, 2007Genzyme Begins Major Expansion of Boston Manufacturing Facility
July 23, 2007Oswaldo Cruz Foundation and Genzyme Corporation Form Collaboration To Advance New Drugs for Neglected Diseases



Search News Releases

 

Financial News

Latest Earnings Report:

Second Quarter 2008

Annual Report:

2007 Annual Report (HTML)
2006 Annual Report (HTML)


CONTACT INFORMATION:
Genzyme Media Relations
500 Kendall Street
Cambridge, MA 02142
T 617 252 7570
F 617 374 7368
Email Media Relations

Terms and Conditions of Use | Privacy Policy | © 2002-2008 Genzyme Corporation. All rights reserved.